[Promising results of the combination of radiotherapy and pembrolizumab in metastatic NSCLC]
- PMID: 32040692
- DOI: 10.1007/s00066-019-01573-z
[Promising results of the combination of radiotherapy and pembrolizumab in metastatic NSCLC]
Comment on
-
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.JAMA Oncol. 2019 Sep 1;5(9):1276-1282. doi: 10.1001/jamaoncol.2019.1478. JAMA Oncol. 2019. PMID: 31294749 Free PMC article.
References
Literatur
-
- Gomez DR, Tang C, Zhang J, Blumenschein GR Jr., Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV (2019) Local Consolidative therapy vs. Maintenance therapy or observation for patients with Oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 37(18):1558–1565. https://doi.org/10.1200/JCO.19.00201 - DOI - PubMed
-
- Derer A, Frey B, Fietkau R, Gaipl US (2015) Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-015-1771-8 - DOI - PubMed
-
- Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr., Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7 - DOI - PubMed
-
- Brooks ED, Chang JY (2019) Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol 16(2):123–135. https://doi.org/10.1038/s41571-018-0119-7 - DOI - PubMed
-
- Hecht M, Buttner-Herold M, Erlenbach-Wunsch K, Haderlein M, Croner R, Grutzmann R, Hartmann A, Fietkau R, Distel LV (2016) PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer 65:52–60. https://doi.org/10.1016/j.ejca.2016.06.015 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
